Cytokinetics CYTK Repayment Of Convertible Debts
Discontinued — last reported Q4 '25
Repayment Of Convertible Debts at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:RepaymentOfConvertibleDebts.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's repayment of convertible debts.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's repayment of convertible debts?
- Cytokinetics (CYTK) reported repayment of convertible debts of $100.63M in Q4 2025.
- What is the long-term trend for Cytokinetics's repayment of convertible debts?
- Over 3 years (2022 to 2025), Cytokinetics's repayment of convertible debts has grown at a 42.1% compound annual growth rate (CAGR), from $140.33M to $402.5M.
- What does repayment of convertible debts mean?
- Cash paid to settle convertible debt obligations.
- How do you interpret repayment of convertible debts?
- Higher repayments indicate the settlement of debt rather than conversion into equity, which may impact cash reserves.
- How does repayment of convertible debts compare across companies?
- Specific to companies utilizing convertible notes as a financing tool; common in high-growth biotech sectors.